Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Carisma Therapeutics Inc.

Healthcare US CARM

0.019USD
0.00(0%)

Last update at 2026-06-22T15:19:00Z

Day Range

0.010.02
LowHigh

52 Week Range

0.0011.27
LowHigh

Fundamentals

  • Previous Close 0.02
  • Market Cap0.04M
  • Volume5556
  • P/E Ratio0.01
  • Dividend Yield-%
  • EBITDA14.18M
  • Revenue TTM52.63M
  • Revenue Per Share TTM1.26
  • Gross Profit TTM 25.28M
  • Diluted EPS TTM0.19

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -60.47700M -86.87900M 3.88M -40.78400M -28.34900M
Minority interest - - - - -
Net income -60.47700M -86.87900M - -40.77400M -28.32000M
Selling general administrative 20.14M 29.52M 39.79M 6.41M 5.09M
Selling and marketing expenses - 8.27M - - -
Gross profit -40.04100M -59.20600M 40.00M 26.54M 11.24M
Reconciled depreciation 3.35M 2.84M - 0.68M 0.45M
Ebit -60.17900M -88.73100M -25.90900M -40.79400M -28.37800M
Ebitda -56.82500M -85.89400M -25.90990M -40.11200M -27.93000M
Depreciation and amortization 3.35M 2.84M -0.00090M 0.68M 0.45M
Non operating income net other - - - - -
Operating income -62.17900M -88.73100M -25.90900M -40.79400M -28.37800M
Other operating expenses 81.81M 103.65M 78.38M 40.79M 28.38M
Interest expense - 1.94M - 8.26M 1.47M
Tax provision - - - - -
Interest income 1.70M 1.94M - 0.01000M 0.03M
Net interest income 1.70M 1.94M - 0.01000M 0.03M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -60.47700M 8.10M 3.88M -0.01000M -0.02900M
Total revenue 19.63M 14.92M 40.00M 26.54M 11.24M
Total operating expenses 22.14M 29.52M 78.38M 40.79M 28.38M
Cost of revenue 59.67M 74.12M - - -
Total other income expense net 1.70M 1.85M 29.78M 0.01000M 0.03M
Discontinued operations - - - - -
Net income from continuing ops -60.47700M -86.87900M - -40.78400M -28.34900M
Net income applicable to common shares - - - -40.78400M -28.34900M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 30.46M 89.55M 189.17M 35.45M 58.46M
Intangible assets - - - 14.70M 46.40M
Earning assets - - - - -
Other current assets 2.13M 2.87M 21.40M 1.24M 1.28M
Total liab 58.37M 63.02M 30.98M 9.43M 8.31M
Total stockholder equity -27.90900M 26.53M 158.19M 11.63M 35.76M
Deferred long term liab - - 4.11M - -
Other current liab 12.24M 8.63M 29.75M 4.47M 1.57M
Common stock 0.04M 0.04M 0.20M 0.20M 0.14M
Capital stock 0.04M 0.04M - 107.81M 91.63M
Retained earnings -305.57900M -245.10200M -336.14100M -96.99700M -56.21300M
Other liab - - - - -
Good will - - - 13.06M 13.06M
Other assets - 0.00000M - - 0.21M
Cash 17.91M 77.61M 112.55M 28.55M 51.79M
Cash and equivalents - - - - -
Total current liabilities 16.05M 15.91M 30.98M 7.69M 5.68M
Current deferred revenue 3.73M 1.41M - - 1.50M
Net debt -15.42800M -74.48200M -112.55300M -25.91900M -48.34300M
Short term debt 1.74M 1.94M - 0.90M 0.81M
Short long term debt - - - - -
Short long term debt total 2.48M 3.12M - 2.63M 3.44M
Other stockholder equity 277.63M 271.59M 494.13M 0.82M 0.34M
Property plant equipment - - 13.45M 5.66M 5.19M
Total current assets 23.82M 80.47M 189.14M 29.79M 53.06M
Long term investments - - - - -
Net tangible assets - - - -96.17900M -55.87400M
Short term investments 0.93M 0.00000M 54.37M - -
Net receivables 2.86M - 0.82M 24.49M -
Long term debt - - - - -
Inventory - - - -41.73400M -
Accounts payable 2.08M 3.93M 1.23M 2.32M 3.29M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -89.55400M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.21M 0.15M 0.03M -27.76400M 0.21M
Deferred long term asset charges - - - - -
Non current assets total 6.63M 9.08M 0.03M 5.66M 5.40M
Capital lease obligations 2.48M 3.12M - 2.63M 3.44M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.12300M 72.41M - -1.87100M -0.44000M
Change to liabilities - - 0.00000M -0.97400M 1.28M
Total cashflows from investing activities -0.12300M 72.41M - -1.87100M -0.44000M
Net borrowings -1.42900M -1.30100M 35.66M 35.66M 35.66M
Total cash from financing activities 0.34M 62.18M 0.00000M 15.96M 72.26M
Change to operating activities - - - 2.44M -1.73500M
Net income -60.47700M -86.87900M -0.01988M -40.78400M -28.34900M
Change in cash -59.69600M 53.41M -162.52242M -23.23700M 44.81M
Begin period cash flow 77.61M 24.19M 162.66M 51.79M 6.98M
End period cash flow 17.91M 77.61M 0.13M 28.55M 51.79M
Total cash from operating activities -59.91700M -81.17700M 0.02M -37.32800M -27.01200M
Issuance of capital stock 2.39M 31.24M - 16.33M 72.24M
Depreciation 3.35M 2.84M -0.00090M 0.68M 0.45M
Other cashflows from investing activities - - - - -
Dividends paid - - - - 0.15M
Change to inventory - - - - -
Change to account receivables - - 0.02M -24.49300M -
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.61900M 32.24M 0.00000M 15.96M -0.44000M
Change to netincome - - - 1.31M 1.34M
Capital expenditures 0.12M 1.13M 4.66M 1.87M 0.44M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -11.95200M -5.43600M 0.04M 1.46M -0.45300M
Stock based compensation 3.65M 2.32M 0.00691M 0.48M 0.16M
Other non cash items 5.51M 5.99M - 0.83M 1.18M
Free cash flow -60.04000M -82.30900M 0.02M -39.19900M -27.45200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CARM
Carisma Therapeutics Inc.		 - -% 0.02 0.01 - 0.0008 114.10 0.0029 0.01
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Carisma Therapeutics Inc.

3675 Market Street, Philadelphia, PA, United States, 19104

Key Executives

Name Title Year Born
Mr. Steven Kelly President, CEO & Director 1965
Mr. Michael Klichinsky Ph.D., Pharm.D., PharmD Co-Founder & Chief Scientific Officer 1990
Mr. Richard S. Morris CPA CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off. 1974
Mr. Saar Gill M.D., Ph.D. Co-Founder NA
Dr. Daniel J. Cushing FCP, Ph.D. Chief Technology & Development Officer NA
Mr. Eric H. Siegel J.D., MBA General Counsel & Corporate Secretary 1965
Ms. Terry Shields Senior Vice President of Human Resources NA
Mr. Tom Wilton Chief Business Officer 1974
Dr. Saar Gill M.D., Ph.D. Co-Founder & Chairman of Scientific Advisory Board NA
Dr. Eugene P. Kennedy F.A.C.S., M.D. Chief Medical Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions